Paolo Gisondi et al., summarize issues faced by many dermatologists during the unprecedented lockdown period in Spring 2020 due to the COVID-19 pandemic. Issues like the sudden cancellation of face-to-face consultations, and the mandatory introduction of telemedicine (after months of a rather optional exercise with this type of caregiving), needed an entrepreneurial approach to manage.

PsoProtectMe now available in multiple languages

IPC Webinar | COVID-19 y psoriasis: Informes ibero-latinoamericanos del IPC

Having cared for psoriasis patients via teledermatology for more than 10 years prior to the pandemic, I recognize the benefits and limitations of teledermatology for managing psoriasis. I would like to share a few practice pearls.

Searching for signals of increased risk of infection in specific subgroups is vitally important, especially when confronted with a severe threat to health, like the worldwide spread of the SARS-CoV-2 virus.

US-based rheumatologist and IPC Councilor Arthur Kavanaugh, MD, discusses his plans to continue offering telemedicine appointments to patients after the pandemic. "Telemedicine is a new skill set that [we] providers need to learn," says Dr. Kavanaugh in this week's Stories from the Field video.

Due to COVID-19 restrictions, patients in Egypt with severe psoriasis are not getting timely access to biologic treatment. IPC Board Member Mahira Hamdy El Sayed, MSc, MD, discusses the potential fallout for Egyptians with psoriasis, post-COVID-19.

Dr. Lluís Puig provides his comments on a recent publication on the classification of the cutaneous manifestations of COVID‐19.

Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.

Soon after COVID-19 was declared a pandemic, the question if particular patient groups – those with immune-mediated inflammatory disease (IMID) and/or those on an immunosuppressant treatment – are at higher risk to become infected and/or are at risk for developing a more severe course of the disease.